534
Participants
Start Date
March 14, 2023
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2032
triptorelin, goserelin, leuprorelin
ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
RECRUITING
Hospital San Francisco de Asís, Madrid
RECRUITING
Hospital Gregorio Marañón, Madrid
RECRUITING
Hospital Ramón y Cajal, Madrid
RECRUITING
Hospital Ruber Internacional, Madrid
NOT_YET_RECRUITING
Hospital Clínico San Carlos, Madrid
RECRUITING
Hospital Universitario Fundación Jiménez Díaz, Madrid
NOT_YET_RECRUITING
Hospital Universitario de La Paz, Madrid
ACTIVE_NOT_RECRUITING
Hospital Universitario HM Sanchinarro, Madrid
RECRUITING
Hospital Universitario Quirón Madrid, Pozuelo de Alarcón
ACTIVE_NOT_RECRUITING
Hospital Universitario de Fuenlabrada, Fuenlabrada
ACTIVE_NOT_RECRUITING
Hospital Universitario Sant Joan de Reus, Tarragona
NOT_YET_RECRUITING
Hospital Universitario y Politécnico de La Fe, Valencia
NOT_YET_RECRUITING
Hospital de Cruces, Barakaldo
NOT_YET_RECRUITING
Instituto Catalán de Oncología Hospitalet, L'Hospitalet de Llobregat
NOT_YET_RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
NOT_YET_RECRUITING
Hospital Clinic de Barcelona, Barcelona
NOT_YET_RECRUITING
Hospital de la Santa Creu i Sant Pau, Barcelona
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
OTHER